Fig. 1Characteristic immunohistochemical expression of epidermal growth factor receptor (EGFR), p53, and isocitrate dehydrogenase 1 (IDH-1) in primary glioblastoma (A-C) and secondary glioblastoma (D-F). EGFR (A, D), p53 (B, E), and IDH-1 (C, F).
Table 1.Immunohistochemical expression of EGFR and p53 in glioblastomas with median age (n=150)
IHC |
No. of cases (%) |
Age (yr) |
p-value |
EGFR(+) |
93/150 (62.7) |
61.2 |
.016 |
p53(+) |
74/150 (49.3) |
53.5 |
< .001 |
EGFR(+)/p53(–) |
62/150 (41.3) |
65.4 |
< .001 |
EGFR(–)/p53(+) |
43/150 (28.7) |
53.8 |
.019 |
EGFR(+)/p53(+) |
31/150 (20.7) |
53.09 |
.126 |
EGFR(–)/p53(–) |
14/150 (9.3) |
57.9 |
.075 |
Table 2.Immunohistochemical expression of IDH-1 in glioblastomas (n=144)
|
IDH-1 positive |
IDH-1 negative |
p-value |
No. of cases |
16 (11.1) |
128 (88.9) |
|
Age (yr) |
45.2 |
60.0 |
< .001 |
Male/Female ratio |
1.33 |
0.56 |
.136 |
Clinically secondary GBM |
4/4 |
0/4 |
.006 |
EGFR(+) |
7/16 (43.8) |
82/128 (64.1) |
.97 |
p53(+) |
14/16 (87.5) |
57/128 (44.5) |
.01 |
Table 3.Immunohistochemical subtypes in clinically primary and secondary glioblastomas (n=144) according to IDH-1, EGFR, and p53 immunohistochemical profiles
IHC |
Clinically primary GBM |
Clinically secondary GBM |
IDH-1(–)/EGFR(+)/p53(–) |
58 (40.2) |
0 (0) |
IDH-1(–)/EGFR(+)/p53(+) |
24 (16.6) |
0 (0) |
IDH-1(–)/EGFR(–)/p53(+) |
33 (22.9) |
0 (0) |
IDH-1(–)/EGFR(–)/p53(–) |
13 (9.0) |
0 (0) |
IDH-1(+)/EGFR(+)/p53(–) |
1 (0.6) |
0 (0) |
IDH-1(+)/EGFR(+)/p53(+) |
6 (4.1) |
0 (0) |
IDH-1(+)/EGFR(–)/p53(–) |
0 (0) |
1 (0.6) |
IDH-1(+)/EGFR(–)/p53(+) |
5 (3.4) |
3 (2.0) |
Table 4.Clinicopathologic profiles of immunohistochemically secondary glioblastomas
Case No. |
Age |
Sex |
Previous Diagnosis |
EGFR |
p53 |
IDH-1 |
1 |
36 |
F |
Diffuse astrocytoma |
– |
– |
+ |
2 |
39 |
M |
Anaplastic astrocytoma |
– |
+ |
+ |
3 |
45 |
M |
Diffuse astrocytoma |
– |
+ |
+ |
4 |
56 |
F |
Anaplastic astrocytoma |
– |
+ |
+ |
5 |
57 |
F |
None |
– |
+ |
+ |
6 |
38 |
M |
None |
– |
+ |
+ |
7 |
69 |
F |
None |
– |
+ |
+ |
8 |
19 |
F |
None |
– |
+ |
+ |
9 |
40 |
M |
None |
– |
+ |
+ |
Table 5.Statistical measures of the performance of a binary classification test in immunohistochemically primary glioblastomas (n=135) according to different antibody combinations
|
Sensitivity |
Specificity |
Accuracy |
PPV |
NPV |
EGFR(+) |
65.93 |
100.00 |
68.06 |
100.00 |
16.36 |
p53(–) |
53.33 |
88.89 |
55.56 |
98.63 |
11.27 |
IDH-1(–) |
94.07 |
100.00 |
94.44 |
100.00 |
52.94 |
EGFR(+) and p53(–) |
43.70 |
100.00 |
47.22 |
100.00 |
10.59 |
EGFR(+) or p53(–) |
90.37 |
11.11 |
85.42 |
93.85 |
7.14 |
IDH-1(–) and EGFR(+) |
60.74 |
100.00 |
63.19 |
100.00 |
14.52 |
IDH-1(–) or EGFR(+) |
100.00 |
100.00 |
100.00 |
100.00 |
100.00 |
IDH-1(–) and p53(–) |
52.59 |
100.00 |
55.56 |
100.00 |
12.33 |
IDH-1(–) or p53(–) |
95.56 |
88.89 |
95.14 |
99.23 |
57.14 |
EGFR(+) and p53(–) and IDH-1(–) |
42.96 |
100.00 |
46.53 |
100.00 |
10.47 |
Table 6.Statistical measures of the performance of a binary classification test in immunohistochemically secondary glioblastomas (n=9) according to different antibody combinations
|
Sensitivity |
Specificity |
Accuracy |
PPV |
NPV |
EGFR(–) |
100.00 |
65.93 |
68.06 |
16.36 |
100.00 |
p53(+) |
88.89 |
53.33 |
55.56 |
11.27 |
98.63 |
IDH-1(+) |
100.00 |
94.81 |
95.14 |
56.20 |
100.00 |
EGFR(–) and p53(+) |
88.89 |
75.56 |
76.39 |
19.51 |
99.03 |
EGFR(–) or p53(+) |
100.00 |
43.70 |
47.22 |
10.59 |
100.00 |
IDH-1(+) and EGFR(–) |
100.00 |
100.00 |
100.00 |
100.00 |
100.00 |
IDH-1(+) or EGFR(–) |
100.00 |
60.74 |
63.19 |
14.52 |
100.00 |
IDH-1(+) and p53(+) |
88.89 |
95.56 |
95.14 |
57.14 |
99.23 |
IDH-1(+) or p53(+) |
100.00 |
53.33 |
56.25 |
12.50 |
100.00 |
EGFR(–) and p53(+) and IDH-1(+) |
88.89 |
100.00 |
99.31 |
100.00 |
99.26 |